Syndax Pharmaceuticals Inc

NASDAQ:SNDX   3:59:58 PM EDT
16.13
+0.02 (+0.12%)
Products, Other Pre-Announcement

Syndax Pharmaceuticals Reports Q3 Loss Per Share $0.40

Published: 11/15/2021 21:44 GMT
Syndax Pharmaceuticals Inc (SNDX) - Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update.
Q3 Loss per Share $0.40.
For Full Year of 2021, Research and Development Expenses Are Expected to Be $90 to $100 Million.
Sees FY of 2021 Total Operating Expenses to Be $110 Million to $120 Million.